Non-ICANS neurotoxicities (NINTs) are serious, atypical toxicities associated with ciltacabtagene autoleucel, a commercial chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory multiple myeloma. Risk factors contributing to the development of NINTs are poorly understood. In a cohort of 109 patients, we identify predisposing risk factors and propose strategies to mitigate NINTs. We show that high peak absolute lymphocyte…
Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel
medRxiv Oncology | | Jurgens, E. M., Bready, B., Derkach, A., Hosszu, K., McAvoy, D., Firestone, R., Rajeeve, S., Lesokhin, A., Korde, N., Tan, C., Hashmi, H., Hassoun, H., Shah, U., Hultcrantz, M., Merz, M., Maura, F., Giralt, S., Shah, G., Landau, H., Scordo, M., Perica, K., Santomasso, B., Park, J., Leslie, C., Usmani, S., Mailankody, S., Mitra, S., Herrera, K., Nemirovsky, D., Maclachlan, K.
Topics: blood-cancer, prevention, research